X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (645) 645
Book Review (115) 115
Publication (46) 46
Conference Proceeding (14) 14
Book Chapter (7) 7
Patent (6) 6
Book / eBook (5) 5
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (459) 459
humans (389) 389
oncology (347) 347
male (228) 228
melanoma (216) 216
female (204) 204
middle aged (166) 166
aged (144) 144
cancer (143) 143
adult (133) 133
animals (123) 123
melanoma - pathology (108) 108
melanoma - drug therapy (107) 107
surgery (101) 101
skin neoplasms - pathology (86) 86
prognosis (79) 79
isolated limb perfusion (75) 75
skin neoplasms - drug therapy (72) 72
aged, 80 and over (71) 71
treatment outcome (70) 70
immunology (69) 69
melanoma - mortality (67) 67
immunotherapy (66) 66
neoplasm staging (65) 65
malignant-melanoma (63) 63
tumor necrosis factor-alpha - administration & dosage (63) 63
melphalan (62) 62
rats (62) 62
cutaneous melanoma (61) 61
interferon-gamma (60) 60
melphalan - administration & dosage (60) 60
metastatic melanoma (56) 56
hematology, oncology and palliative medicine (54) 54
survival (53) 53
medicine & public health (52) 52
care and treatment (51) 51
chemotherapy, cancer, regional perfusion (51) 51
disease-free survival (51) 51
tnf-alpha (51) 51
antineoplastic agents - therapeutic use (50) 50
skin neoplasms - mortality (50) 50
metastasis (49) 49
melanoma - surgery (48) 48
chemotherapy (47) 47
sarcoma (47) 47
tumors (46) 46
melanoma - secondary (45) 45
melanoma - therapy (44) 44
review (44) 44
chemotherapy, cancer, regional perfusion - methods (43) 43
mice (43) 43
therapy (43) 43
abridged index medicus (42) 42
tumor-necrosis-factor (42) 42
research (41) 41
survival rate (41) 41
extremities (38) 38
lymphatic metastasis (38) 38
surgical oncology (38) 38
health aspects (37) 37
adjuvant therapy (36) 36
adolescent (36) 36
antineoplastic agents - administration & dosage (36) 36
analysis (35) 35
ipilimumab (34) 34
skin neoplasms - surgery (34) 34
survival analysis (34) 34
combined modality therapy (33) 33
follow-up studies (33) 33
sarcoma - drug therapy (33) 33
antineoplastic combined chemotherapy protocols - therapeutic use (32) 32
interferon-alpha - therapeutic use (31) 31
retrospective studies (31) 31
lymph node excision (30) 30
time factors (30) 30
trial (30) 30
antineoplastic agents, alkylating - administration & dosage (29) 29
chemotherapy, adjuvant (29) 29
high-risk melanoma (29) 29
medicine, research & experimental (29) 29
combination (28) 28
factor-alpha (28) 28
interferon (28) 28
sentinel lymph node biopsy (28) 28
clinical trials (27) 27
metastases (27) 27
pharmacology & pharmacy (27) 27
risk factors (27) 27
biopsy (26) 26
prognostic-factors (26) 26
young adult (26) 26
neoplasm metastasis (25) 25
expression (24) 24
melanoma - immunology (24) 24
skin neoplasms - therapy (24) 24
clinical trials as topic (23) 23
kaplan-meier estimate (23) 23
antibodies, monoclonal - therapeutic use (22) 22
antineoplastic agents - pharmacology (22) 22
breast-cancer (22) 22
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2007, Cancer drug discovery and development, ISBN 1588296725, xiv, 455
This volume provides a biological and pharmacological background for regional cancer therapy, strategies and techniques for regional therapies, and specific... 
Clinical & internal medicine | Cancer | Surgical oncology | Cancer Research | Oncology | Biomedicine | Radiotherapy | Surgical Oncology | Surgery | Drug targeting | Antineoplastic agents | Infusion therapy
Book
by Gershenwald, Jeffrey E and Scolyer, Richard A and Hess, Kenneth R and Sondak, Vernon K and Long, Georgina V and Ross, Merrick I and Lazar, Alexander J and Faries, Mark B and Kirkwood, John M and McArthur, Grant A and Haydu, Lauren E and Eggermont, Alexander M. M and Flaherty, Keith T and Balch, Charles M and Thompson, John F and Gershenwald, Jeffrey E and Scolyer, Richard A and Atkins, Michael B and Balch, Charles M and Barnhill, Raymond L and Bilimoria, Karl Y and Buzaid, Antonio C and Byrd, David R and Cochran, Alistair J and Eggermont, Alexander M. M and Elder, David E and Faries, Mark B and Flaherty, Keith T and Garbe, Claus and Gardner, Julie M and Gimotty, Phyllis A and Halpern, Allan C and Haydu, Lauren E and Hess, Kenneth R and Johnson, Timothy M and Kirkwood, John M and Lazar, Alexander J and Lee, Anne W. M and Long, Georgina V and McArthur, Grant A and Mihm Jr, Martin C and Prieto, Victor G and Ross, Merrick I and Sober, Arthur J and Sondak, Vernon K and Thompson, John F and Wong, Sandra L and Delman, Keith A and Santinami, Mario and Maurichi, Andrea and Nagore, Eduardo and Faries, Mark B and Thompson, John F and Scolyer, Richard A and McArthur, Grant A and Gyorki, David E and Henderson, Michael and Stratigos, Alexander J and Gogas, Helen and Gershenwald, Jeffrey E and Haydu, Lauren E and Rossi, Carlo Riccardo and Sommariva, Antonio and American Joint Comm Canc Melanoma and Int Melanoma Database Discovery and for members of the American Joint Committee on Cancer Melanoma Expert Panel and the International Melanoma Database and Discovery Platform
CA: A Cancer Journal for Clinicians, ISSN 0007-9235, 11/2017, Volume 67, Issue 6, pp. 472 - 492
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 5, pp. 522 - 530
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 19, pp. 1789 - 1801
A blinded trial involving patients with resected stage III melanoma showed that adjuvant pembrolizumab every 3 weeks for a year was associated with a 1-year... 
HIGH-RISK MELANOMA | SURVIVAL | MEDICINE, GENERAL & INTERNAL | ANTI-PD-1 THERAPY | EORTC 18952 | TUMOR BURDEN | CUTANEOUS MELANOMA | PHASE-3 TRIAL | PEGYLATED INTERFERON-ALPHA-2B | NODE-POSITIVE MELANOMA | IPILIMUMAB | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Adjuvants, Immunologic - adverse effects | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - surgery | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Kaplan-Meier Estimate | Neoplasm Recurrence, Local | Survival Rate | Disease-Free Survival | B7-H1 Antigen - antagonists & inhibitors | Melanoma - drug therapy | Intention to Treat Analysis | Quality of Life | Aged | B7-H1 Antigen - analysis | Infusions, Intravenous | Melanoma - surgery | Neoplasm Staging | Melanoma - mortality | Diagnosis | Drug therapy | Patients | Health aspects | Melanoma | Medical research | Lymphatic system | Risk groups | PD-1 protein | Committees | Metastasis | Survival | Skin cancer | Pembrolizumab | Hospitals | Motivation | PD-L1 protein | Myositis | Death | Mutation | Tumors | Cancer | Index Medicus | Abridged Index Medicus | Placebos | Placebos (Medicine) | Adjuvant treatment of cancer | Tractament adjuvant del càncer
Journal Article
Annals of Surgical Oncology, ISSN 1068-9265, 12/2017, Volume 24, Issue S3, pp. 661 - 662
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1245/s10434-017-6230-7 
Oncology | Medicine & Public Health | Surgical Oncology | Surgery | SENTINEL NODES | SURGERY | ONCOLOGY | CUTANEOUS MELANOMA | Usage | Melanoma | Metastasis | Index Medicus
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 2014, Volume 11, Issue 5, pp. 248 - 249
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2016, Volume 375, Issue 19, pp. 1845 - 1855
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 01/2017, Volume 376, Issue 4, p. 399
Journal Article
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 05/2009, Volume 6, Issue 5, pp. 256 - 258
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 26, pp. 2507 - 2516
Journal Article